147 related articles for article (PubMed ID: 20602196)
1. Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer.
Siemerink EJ; Drenth AF; Mulder NH; Plukker JT; Hospers GA
Gastric Cancer; 2010 Jun; 13(2):95-100. PubMed ID: 20602196
[TBL] [Abstract][Full Text] [Related]
2. 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Bennouna J; Perrier H; Paillot B; Priou F; Jacob JH; Hebbar M; Bordenave S; Seitz JF; Cvitkovic F; Dorval E; Malek K; Tonelli D; Douillard JY
Br J Cancer; 2006 Jan; 94(1):69-73. PubMed ID: 16404362
[TBL] [Abstract][Full Text] [Related]
3. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
[TBL] [Abstract][Full Text] [Related]
4. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Petrioli R; Sabatino M; Fiaschi AI; Marsili S; Pozzessere D; Messinese S; Correale P; Civitelli S; Tanzini G; Tani F; De Martino A; Marzocca G; Lorenzi M; Giorgi G; Francini G
Br J Cancer; 2004 Jan; 90(2):306-9. PubMed ID: 14735168
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer.
Chen JS; Huang JS; Yang TS; Lin YC; Wang HM; Liau CT; Rau KM
Anticancer Drugs; 2005 Jan; 16(1):47-51. PubMed ID: 15613903
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
7. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Feliu J; Vicent JM; García-Girón C; Constela M; Fonseca E; Aparicio J; Lomas M; Antón-Aparicio L; Dorta FJ; Gonzalez-Baron M;
Br J Cancer; 2004 Nov; 91(10):1758-62. PubMed ID: 15505621
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
Rosati G; Cordio S; Tucci A; Blanco G; Bordonaro R; Reggiardo G; Manzione L
Oncology; 2005; 69(2):122-9. PubMed ID: 16118508
[TBL] [Abstract][Full Text] [Related]
11. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Bajetta E; Di Bartolomeo M; Buzzoni R; Mariani L; Zilembo N; Ferrario E; Lo Vullo S; Aitini E; Isa L; Barone C; Jacobelli S; Recaldin E; Pinotti G; Iop A
Br J Cancer; 2007 Feb; 96(3):439-44. PubMed ID: 17245343
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
Kim YH; Shin SW; Kim BS; Park YT; Kim JG; Kim JS
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):119-23. PubMed ID: 9348583
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
14. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
Sheikh HY; Valle JW; Waddell T; Palmer K; Wilson G; Sjursen A; Craven O; Swindell R; Saunders MP
Br J Cancer; 2008 Aug; 99(4):577-83. PubMed ID: 18682717
[TBL] [Abstract][Full Text] [Related]
15. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
16. UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial.
Ravaud A; Borner M; Schellens JH; Geoffrois L; Schöffski BP; Kroon K; Wanders J; Hanauske AR; Fumoleau P;
Eur J Cancer; 2001 Sep; 37(13):1642-7. PubMed ID: 11527690
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients.
Somali I; Meydan N; Tarhan MO; Oztop I; Alacacioglu A; Yilmaz U
J BUON; 2009; 14(3):429-33. PubMed ID: 19810134
[TBL] [Abstract][Full Text] [Related]
18. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
19. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
Lin PC; Chen WS; Chao TC; Yang SH; Tiu CM; Liu JH
Cancer Chemother Pharmacol; 2007 Aug; 60(3):351-6. PubMed ID: 17111120
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Lee J; Kang WK; Kwon JM; Oh SY; Lee HR; Kim HJ; Park BB; Lim HY; Han MJ; Park JO; Park YS
Ann Oncol; 2007 Jan; 18(1):88-92. PubMed ID: 16971670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
